{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 232, 'offsetInEndSection': 491, 'text': 'Almost all cases of HAE are caused by mutations in the SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI), a serine protease inhibitor that normally inhibits proteases in the contact, complement, and fibrinolytic systems', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30059156'}]\n\n\n                 'Which gene is most frequently mutated in hereditary angioedema ?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"SERPING1\", \"C1NH\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 217, 'text': 'Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35617368'}, {'offsetInBeginSection': 134, 'offsetInEndSection': 420, 'text': 'We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine (ZF2001, hereafter referred to as ZF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35617368'}, {'offsetInBeginSection': 3124, 'offsetInEndSection': 3314, 'text': 'CONCLUSIONS: Heterologous boosting with ZF2001 following primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35617368'}, {'offsetInBeginSection': 1434, 'offsetInEndSection': 1539, 'text': 'Conclusion: SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634276'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 93, 'text': 'Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35596222'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 260, 'text': 'To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35596222'}, {'offsetInBeginSection': 97, 'offsetInEndSection': 233, 'text': 'Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35568034'}]\n\n\n                 'ZF2001 is used for which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"COVID-19\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 615, 'offsetInEndSection': 748, 'text': 'Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\xa0= 6),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29706521'}, {'offsetInBeginSection': 73, 'offsetInEndSection': 136, 'text': 'Indian Muntjac, a Placental Mammal with Only Three Chromosomes.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31879909'}, {'offsetInBeginSection': 1373, 'offsetInEndSection': 1457, 'text': ' Indian muntjac, a placental mammal with the lowest known chromosome number (n\\xa0=\\xa03).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31879909'}, {'offsetInBeginSection': 615, 'offsetInEndSection': 848, 'text': 'Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\xa0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29706521'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/5444269'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'The Indian muntjac is believed to have the lowest chromosome number in mammals (2n = 6 in females and 2n = 7 in males).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8485991'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'The Indian muntjac, an asiatic deer, has the lowest diploid chromosome number among mammals (female 2N = 6; male 2N = 7).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8513693'}, {'offsetInBeginSection': 233, 'offsetInEndSection': 709, 'text': 'By combining molecular perturbations and phenotypic analyses in Indian muntjac fibroblasts containing the lowest known diploid chromosome number in mammals (2N\\xa0= 6) and distinctively large kinetochores, with fixed/live-cell super-resolution coherent-hybrid stimulated emission depletion (CH-STED) nanoscopy and laser microsurgery, we demonstrate a key role for augmin in kinetochore microtubule self-organization and maturation, regardless of pioneer centrosomal microtubules.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35385739'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 182, 'text': 'The karyotype of Indian muntjacs (Muntiacus muntjak vaginalis) has been greatly shaped by chromosomal fusion, which leads to its lowest diploid number among the extant known mammals.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16791631'}, {'offsetInBeginSection': 614, 'offsetInEndSection': 848, 'text': ' Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\xa0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29706521'}]\n\n\n                 'What mammal has the lowest known chromosome number?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Indian muntjac\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 194, 'text': 'Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\u00ae), Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21426252'}]\n\n\n                 'Which company produces Ruconest?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Pharming\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1254, 'offsetInEndSection': 1482, 'text': 'The mean [median] ages in years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase (CK), 4.6 [4.6]; DNA/muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.2 [1.4].', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35312090'}, {'offsetInBeginSection': 505, 'offsetInEndSection': 547, 'text': 'The mean age of diagnosis was 4.43\\u2009years. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31573675'}, {'offsetInBeginSection': 646, 'offsetInEndSection': 693, 'text': ' The mean age for DMD diagnosis was 4.9 years. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7557061'}, {'offsetInBeginSection': 809, 'offsetInEndSection': 920, 'text': 'In 10 cases of the group with locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7557061'}, {'offsetInBeginSection': 647, 'offsetInEndSection': 692, 'text': 'The mean age for DMD diagnosis was 4.9 years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7557061'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 488, 'text': 'lso frequent. The average age at diagnosis is 4.83 years but an early diagnosis is possible.CLINICAL CASE: An 18-month male infant in ambulatory study for failure to thrive and malnutrition was admitted in our hospi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334'}, {'offsetInBeginSection': 102, 'offsetInEndSection': 298, 'text': 'The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16322188'}, {'offsetInBeginSection': 286, 'offsetInEndSection': 364, 'text': ' The average age at diagnosis is 4.83 years but an early diagnosis is possible', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334'}, {'offsetInBeginSection': 128, 'offsetInEndSection': 263, 'text': 'ive loss of muscle function. Despite technological advances in diagnostic genetic testing, the mean age at diagnosis (4.7 years) has re', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23494880'}]\n\n\n                 'What is usually the age of diagnosis in Duchenne muscular dystrophy?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"4.43 years old\", \"4.9 years old\", \"between 3 and 11 years of age\", \"4.9 years\", \"3 - 5 years\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 12, 'offsetInEndSection': 172, 'text': 'Conestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24556385'}]\n\n\n                 'Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Conestat alfa\", \"Ruconest\", \"rhC1INH\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 694, 'offsetInEndSection': 829, 'text': 'Viltolarsen restores the reading frame of the DMD gene by skipping \\xa0exon 53\\xa0and produces a truncated but functional form of dystrophin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 501, 'offsetInEndSection': 705, 'text': 'In March 2020, intravenous viltolarsen received its first global approval in Japan for the treatment of DMD in patients with confirmed deletion of the dystrophin gene that is amenable to exon 53 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32519222'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 305, 'text': 'Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}, {'offsetInBeginSection': 594, 'offsetInEndSection': 762, 'text': 'Viltolarsen, also known as NS-065/NCNP-01, is a PMO developed through comprehensive sequence optimization and is designed to skip exon 53 on the DMD primary transcript.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31720560'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 187, 'text': 'OBJECTIVE: The novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystr', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33285037'}, {'offsetInBeginSection': 264, 'offsetInEndSection': 500, 'text': 'Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32519222'}, {'offsetInBeginSection': 264, 'offsetInEndSection': 386, 'text': 'Viltolarsen is a drug of phosphorodiamidate morpholino oligomer (PMO) chemistry, designed to skip exon 53 of the DMD gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34938127'}, {'offsetInBeginSection': 482, 'offsetInEndSection': 569, 'text': ' Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32483212'}, {'offsetInBeginSection': 331, 'offsetInEndSection': 506, 'text': ' Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401027'}, {'offsetInBeginSection': 420, 'offsetInEndSection': 570, 'text': 'en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32947786'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 546, 'text': 'Importance: An unmet need remains for safe and efficacious treatments for Duchenne muscular dystrophy (DMD). To date, there are limited agents available that address the underlying cause of the disease.Objective: To evaluate the safety, tolerability, and efficacy of viltolarsen, a novel antisense oligonucleotide, in participants with DMD amenable to exon 53 skipping.Design, Setting, and Participants: This phase 2 study was a 4-week randomized clinical trial for safety followed by a 20-week open-label treatment period of patients aged 4 to 9', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32453377'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 530, 'text': 'BACKGROUND: Duchenne muscular dystrophy (DMD) is a rare, genetic disease caused by mutations in the DMD gene resulting in an absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. Herein, long-term (>2 years) functional outcomes in viltolarsen treated patients were compared to a matched historical control group.OBJECTIVE: To evaluate long-term efficacy and safety of the anti-sense oligonucleotide viltolarsen in the treatment of patients wit', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634851'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 705, 'text': 'Viltolarsen (Viltepso\u00ae in Japan) is a phosphorodiamidate morpholino antisense oligonucleotide being developed by Nippon Shinyaku, in collaboration with the National Center of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. In March 2020, intravenous viltolarsen received its first global approval in Japan for the treatment of DMD in patients with confirmed deletion of the dystrophin gene that is amenable to exon 53 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32519222'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022'}]\n\n\n                 'What type of DMD can viltolarsen be used for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"exon 53\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 53, 'offsetInEndSection': 192, 'text': 'treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34420980'}, {'offsetInBeginSection': 139, 'offsetInEndSection': 269, 'text': 'A relationship between exon skipping and dystrophin production in exon 51-amenable patients treated with eteplirsen (EXONDYS 51\u00ae) ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33523015'}]\n\n\n                 'What types of DMD can eteplirsen be used for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"exon-51 amenable genetic mutations\", \"exon 51-amenable patients\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 612, 'offsetInEndSection': 781, 'text': 'From these data, we inferred an additional hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose-terminated glycoproteins. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3089897'}, {'offsetInBeginSection': 321, 'offsetInEndSection': 522, 'text': ' This study was designed to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3610047'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 172, 'text': 'The asialoglycoprotein receptor (ASGPR) is a hepatic receptor that mediates removal of potentially hazardous glycoconjugates from blood in health and disease. T', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22919488'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 178, 'text': 'The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18488037'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20816169'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 179, 'text': 'The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18488037'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 193, 'text': 'The endocytic Ashwell-Morell receptor (AMR) of hepatocytes detects pathogen remodeling of host glycoproteins by neuraminidase in the bloodstream and mitigates the lethal coagulopathy of sepsis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24284176'}, {'offsetInBeginSection': 293, 'offsetInEndSection': 581, 'text': 'Platelet-derived antibacterial peptides are important in bloodstream defense against SA, but \u03b1-toxin decreased platelet viability, induced platelet sialidase to cause desialylation of platelet glycoproteins, and accelerated platelet clearance by the hepatic Ashwell-Morell receptor (AMR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33762439'}, {'offsetInBeginSection': 322, 'offsetInEndSection': 522, 'text': 'This study was designed to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3610047'}, {'offsetInBeginSection': 765, 'offsetInEndSection': 946, 'text': 'This leads to platelet clearance in the liver via hepatocyte Ashwell-Morell receptors, which is fundamentally different from the classical Fc-Fc\u03b3R-dependent macrophage phagocytosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26185093'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 391, 'text': 'The mammalian asialoglycoprotein receptor (ASGPR) is located on the sinusoidal membrane of hepatocytes where it binds and endocytoses galactose-terminated glycoproteins (asialoglycoproteins). ASGPR is composed of two highly homologous subunits, termed hepatic lectin 1 and 2. Despite numerous studies the contribution of both subunits to biosynthesis and functional activity of ASGPR in vivo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8702886'}]\n\n\n                 'In what organ would you find the Ashwell receptor?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"liver\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 568, 'offsetInEndSection': 760, 'text': 'Casimersen received its first approval on 25\\xa0February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\xa045 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33861387'}]\n\n\n                 'What type of DMD can casimersen be used for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"exon 45\", \"confirmed mutation of the DMD gene that is amenable to exon 45 skipping\", \"amenable to exon 45\", \"amenable to exon 45 skipping\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'BACKGROUND: CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum infection in a phase 1 clinical trial. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36317783'}, {'offsetInBeginSection': 281, 'offsetInEndSection': 485, 'text': 'METHODS: We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum infection in healthy adults in Mali over a 6-month malaria season.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36317783'}, {'offsetInBeginSection': 1748, 'offsetInEndSection': 1887, 'text': 'CONCLUSIONS: CIS43LS was protective against P. falciparum infection over a 6-month malaria season in Mali without evident safety concerns. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36317783'}, {'offsetInBeginSection': 1150, 'offsetInEndSection': 1306, 'text': 'Based on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria prevention.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33332286'}, {'offsetInBeginSection': 104, 'offsetInEndSection': 342, 'text': 'METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34379916'}, {'offsetInBeginSection': 1910, 'offsetInEndSection': 2095, 'text': 'CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34379916'}]\n\n\n                 'What is targeted by CIS43LS?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Plasmodium falciparum\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 73, 'text': 'RNA polymerases initiate transcription at DNA sequences called promoters.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32297955'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 363, 'text': 'Polymerases are integral factors of gene expression and are essential for the maintenance and transmission of genetic information. RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 392, 'text': 'conventional transcription factors trigger transcription by the RNA polymerase II (pol II) paused within the proximal promoter region.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18648001'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 238, 'text': 'RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2, where RNA polymerase binds in a heparin-resistant manner.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11298753'}, {'offsetInBeginSection': 275, 'offsetInEndSection': 431, 'text': 'The binding region of the RNA polymerase extends from 30 base pairs (bp) upstream (-30) to 20 bp downstream (+20) from the in vivo transcription start site.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2497942'}, {'offsetInBeginSection': 724, 'offsetInEndSection': 921, 'text': 'It is concluded that RNA polymerase binding site and initiation site are identical parts of a promoter region, and that no \"drift\" between these sites is required as a step in RNA chain initiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1175600'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Eukaryotic RNA polymerase I promoter binding is directed by protein contacts with transcription initiation factor and is DNA sequence-independent.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3113736'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'A Drosophila RNA polymerase II transcription factor contains a promoter-region-specific DNA-binding activity.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6537904'}, {'offsetInBeginSection': 529, 'offsetInEndSection': 667, 'text': 'We infer that polymerase is directed to the promoter by a DNA sequence-independent mechanism, solely by protein-protein contacts with TIF.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3113736'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 128, 'text': 'BACKGROUND: RNA Polymerase II (RNAP II) is recruited to core promoters by the pre-initiation complex (PIC) of general transcript', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17997859'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 363, 'text': ' RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129'}, {'offsetInBeginSection': 131, 'offsetInEndSection': 363, 'text': 'RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 706, 'text': 'Regulatory information for transcription initiation is present in a stretch of genomic DNA, called the promoter region that is located upstream of the transcription start site (TSS) of the gene. The promoter region interacts with different transcription factors and RNA polymerase to initiate transcription and contains short stretches of transcription factor binding sites (TFBSs), as well as structurally unique elements. Recent experimental and computational analyses of promoter sequences show that they often have non-B-DNA structural motifs, as well as some conserved structural properties, such as stability, bendability, nucleosome positioning preference and curvature, across a class of organisms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24503515'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 260, 'text': 'Early work identified two promoter regions, the -10 and -35 elements, that interact sequence specifically with bacterial RNA polymerase (RNAP). However, we now know that several additional promoter elements contact RNAP and influence transcription initiation. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18521075'}]\n\n\n                 'To which region of a gene does an RNA polymerase bind to initiate transcription?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Promoter\", \"DNA sequences called promoters\", \"Promoter region\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 11, 'offsetInEndSection': 195, 'text': ' Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34924398'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Duchenne muscular dystrophy is a progressive disease with loss of ambulation at around 9-10 years of age, followed, if untreated, by development of scoliosis, respiratory insufficiency, and death in the second decade of life.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27382620'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 369, 'text': 'BACKGROUND: Duchenne muscular dystrophy (DMD) is the most frequent genetic neuromuscular disease in childhood with loss of ambulation usually occurring around the age of 9-11\\xa0years.OBJECTIVE, MATERIAL AND METHODS: Based on current guidelines and clinical trials, neuropediatric and neurological experts developed recommendations for the treatment of nonambulatory DMD p', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33215271'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 74, 'text': 'Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21784636'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': 'Duchenne muscular dystrophy is the most common and most severe form of childhood muscular dystrophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12026233'}, {'offsetInBeginSection': 635, 'offsetInEndSection': 816, 'text': 'Loss of walking ability occurred in the control group at an average of 9.29 years (5.85-13.63, SD 1.98) and in the operated group at an average of 10.55 years (8.17-14.39, SD 1.76).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10382913'}, {'offsetInBeginSection': 136, 'offsetInEndSection': 303, 'text': ' The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26022172'}, {'offsetInBeginSection': 226, 'offsetInEndSection': 376, 'text': 'it disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26022172'}, {'offsetInBeginSection': 93, 'offsetInEndSection': 243, 'text': 'trophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties. Despite the phenomenal advance', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12026233'}, {'offsetInBeginSection': 211, 'offsetInEndSection': 361, 'text': 'ked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or ca', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16322188'}, {'offsetInBeginSection': 971, 'offsetInEndSection': 1058, 'text': 'Loss of independent gait occurred at similar ages in both groups (10.3 vs. 10.5 years).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12466073'}, {'offsetInBeginSection': 261, 'offsetInEndSection': 414, 'text': 'Subsequently, the disease immobilizes the patient (ages 9 to 14 years) and severe respiratory failure occurs due to chest and vertebral column deformity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17388226'}, {'offsetInBeginSection': 99, 'offsetInEndSection': 249, 'text': ' childhood with loss of ambulation usually occurring around the age of 9-11\\xa0years.OBJECTIVE, MATERIAL AND METHODS: Based on current guidelines and cli', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33215271'}, {'offsetInBeginSection': 214, 'offsetInEndSection': 364, 'text': ' by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or cardi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16322188'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 458, 'text': 'To assess the effect of subcutaneous (s.c.) lower limb tenotomies on the ambulatory ability of patients with Duchenne muscular dystrophy (DMD), 54 patients were followed. Twenty-nine patients underwent hip, knee, and ankle tenotomies at a mean age of 10 2/12 years and were followed postoperatively for an average of 3 9/12 years. These children continued ambulation in long-leg braces to a mean age of 12 8/12 years and stood to an average of 13 5/12 years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8496368'}]\n\n\n                 'At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"7-13 years of age\", \"between 7-13 years of age\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30852095'}, {'offsetInBeginSection': 306, 'offsetInEndSection': 522, 'text': 'We propose that plants employ AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to reduce the metabolic cost of translating all AS transcripts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30852095'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 186, 'text': 'Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29074233'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 253, 'text': 'Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22961303'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'Alternative splicing (AS), in higher eukaryotes, is one of the mechanisms of post-transcriptional regulation that generate multiple transcripts from the same gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24369421'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 245, 'text': 'Over the past decade, alternative splicing has been progressively recognized as a major mechanism regulating gene expression patterns in different tissues and disease states through the generation of multiple mRNAs from the same gene transcript.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26273603'}, {'offsetInBeginSection': 317, 'offsetInEndSection': 497, 'text': 'Alternative splicing is a physiological process by which cells generate several transcripts from one single gene and may in turn give rise to different proteins from the same gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35269461'}, {'offsetInBeginSection': 274, 'offsetInEndSection': 490, 'text': 'However, as well as conventional splicing, several genes have the inherent capacity to undergo alternative splicing, thus allowing synthesis of multiple gene transcripts, perhaps with different functional properties.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16054339'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 159, 'text': 'Alternative splicing (AS) increases the proteomic and functional capacity of genomes through the generation of alternative mRNA transcripts from the same gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18088312'}, {'offsetInBeginSection': 136, 'offsetInEndSection': 226, 'text': 'Indeed, through AS individual gene loci can generate multiple RNAs from the same pre-mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25577391'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Alternative splicing is an important biological process in the generation of multiple functional transcripts from the same genomic sequences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26327458'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 222, 'text': 'Alternative splicing generates multiple transcript and protein isoforms from a single gene and controls transcript intracellular localization and stability by coupling to mRNA export and nonsense-mediated mRNA decay (NMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33406240'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Alternative Splicing (AS) is a mechanism that generates different mature transcripts from precursor mRNAs (pre-mRNAs) of the same gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31921258'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Alternative splicing is a widespread mechanism in mammals that generates several mRNAs from one gene, thereby creating genetic diversity of the genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16611169'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 160, 'text': 'Alternative pre-mRNA splicing plays a very important role in expanding protein diversity as it generates numerous transcripts from a single protein-coding gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34440445'}, {'offsetInBeginSection': 378, 'offsetInEndSection': 534, 'text': ' This task is complicated due to the complexity of alternative splicing - a mechanism by which the same gene may generate multiple distinct RNA transcripts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484809'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Alternative splicing of pre-mRNA is one of the main mechanisms regulating gene expression that generates multiple transcripts from one gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28064309'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28402429'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 103, 'text': 'Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34383135'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': 'Alternative splicing of messenger RNA (mRNA) precursors generates multiple transcripts from a single primary transcript.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18817741'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 223, 'text': 'Among eukaryotic organisms, alternative splicing is an important process that can generate multiple transcripts from one same precursor messenger RNA, which greatly increase transcriptome and proteome diversity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32811430'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 156, 'text': ' Alternative splicing (AS) is a pre-mRNA maturation process leading to the expression of multiple mRNA variants from the same primary transcript.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21896509'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 375, 'text': 'Alternative splicing (AS) is a process that produces various mRNA splicing isoforms via different splicing patterns of mRNA precursors (pre-mRNAs). AS is the primary mechanism for increasing the types and quantities of proteins to improve biodiversity and influence multiple biological processes, including chromatin modification, signal transduction, and protein expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33629774'}, {'offsetInBeginSection': 144, 'offsetInEndSection': 274, 'text': 'Alternative splicing generates multiple transcripts from a single gene, enriching the diversity of proteins and phenotypic traits.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35821097'}]\n\n\n                 'What is the process that generates multiple transcripts from the same gene?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Alternative splicing\", \"Alternative splicing (AS)\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1083, 'offsetInEndSection': 1315, 'text': 'Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645707'}, {'offsetInBeginSection': 1038, 'offsetInEndSection': 1411, 'text': 's (95% confidence interval [CI] 21.2, 22.4). Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3).DISCUSSION: This article presents a full overview of mortality across the lifetime of a patient', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645707'}, {'offsetInBeginSection': 123, 'offsetInEndSection': 246, 'text': 'Over the course of the last century, the average life expectancy of these patients has doubled and now stands at \u223c25\\u2005years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26153505'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': 'Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder with increasing life expectancy from late teens to over 30\\xa0years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34802091'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'The special medical care in the National Sanatorium prolonged the life span of the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1450492'}]\n\n\n                 'What is the life expectancy for Duchenne muscular dystrophy patients?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"28.1 years of age\", \"28.1 years (95% CI 25.1, 30.3)\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 892, 'offsetInEndSection': 1129, 'text': '. Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628152'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'The hormone erythroferrone (ERFE) is produced by erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone hepcidin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34614145'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34614145'}, {'offsetInBeginSection': 825, 'offsetInEndSection': 1012, 'text': 'Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31723763'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 199, 'text': 'Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35464433'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 259, 'text': 'The hormone erythroferrone (ERFE) is produced by erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone hepcidin, thereby mobilizing iron for erythropoiesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34614145'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Erythroferrone (ERFE) is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulation by BMP6.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31899794'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28739636'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 396, 'text': 'Erythroferrone (ERFE) is an iron-regulatory hormone which is highly expressed in erythroblasts by erythropoietin (EPO) stimulation and osteoblasts independently of EPO by sequestering bone morphogenetic proteins and inhibiting hepatic hepcidin expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34772005'}, {'offsetInBeginSection': 354, 'offsetInEndSection': 418, 'text': 'ERFE is produced by erythroblasts in response to erythropoietin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880340'}, {'offsetInBeginSection': 353, 'offsetInEndSection': 418, 'text': ' ERFE is produced by erythroblasts in response to erythropoietin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880340'}, {'offsetInBeginSection': 117, 'offsetInEndSection': 274, 'text': 'Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30097509'}, {'offsetInBeginSection': 305, 'offsetInEndSection': 455, 'text': 'pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880340'}, {'offsetInBeginSection': 894, 'offsetInEndSection': 1129, 'text': 'Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628152'}, {'offsetInBeginSection': 1704, 'offsetInEndSection': 1964, 'text': 'The paradigm is non-transfusion-dependent thalassemia where the release of erythroferrone from the expanded pool of immature erythroid cells results in hepcidin suppression and secondary iron overload that in turn worsens ineffective erythropoiesis and anemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31649559'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 437, 'text': 'Decreased hepcidin mobilizes iron, which facilitates erythropoiesis, but excess iron is pathogenic in \u03b2-thalassemia. Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism. The BMP/SMAD pathway in the liver is critical for hepcidin control, and we show that EPO suppressed hepcidin and other BMP target genes in vivo in a partially ERF', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30097509'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 421, 'text': 'Background: Erythroblast erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis.Methods: To address whether ERFE functions also in bone and whether the mechanism of ERFE action in bone involves BMPs, we utilize the Erfe-/- mouse model as well as \u03b2-thalassemic (Hbbth3/+) mice with systemic loss', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34002695'}]\n\n\n                 'What cells produce erythroferrone?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"erythroid precursors\", \"Erythroblasts\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': 'Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep track of its extent and details of application. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33226222'}]\n\n\n                 'What does FBDD stand for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"fragment-based drug discovery\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 188, 'offsetInEndSection': 313, 'text': \"Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36255625'}]\n\n\n                 'What are PROTACs?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS)\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 631, 'offsetInEndSection': 773, 'text': 'Paclitaxel, docetaxel, doxorubicin, and epirubicin have been longstanding,\\xa0Food and Drug Administration (FDA)-approved therapies against TNBC.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35976445'}]\n\n\n                 'Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Triple negative breast cancer\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006441'}, {'offsetInBeginSection': 224, 'offsetInEndSection': 406, 'text': 'The bispecific antibodies teclistamab (BCMA\u00d7CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\u00d7CD3) are in clinical development as therapies for MM. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006441'}]\n\n\n                 'Talquetamab was developed for treatment of which disease?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"multiple myeloma\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 166, 'offsetInEndSection': 672, 'text': 'Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated and GalNAc-conjugated siRNA therapeutics has resulted in recent FDA approvals of the first siRNA-based drugs, patisiran for the treatment of hereditary transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyria, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33928570'}, {'offsetInBeginSection': 260, 'offsetInEndSection': 529, 'text': 'the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes, N-acetylgalactosamine,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35997897'}, {'offsetInBeginSection': 343, 'offsetInEndSection': 476, 'text': 'GalNAc-conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35819583'}, {'offsetInBeginSection': 164, 'offsetInEndSection': 342, 'text': 'hree such products (givosiran, lumasiran and inclisiran) are liver-targeted, using tris N-acetylgalactosamine (GalNAc)3 as the targeting ligand. Upon subcutaneous administration,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35819583'}, {'offsetInBeginSection': 550, 'offsetInEndSection': 726, 'text': 'Beyond that, we show that GalNAc-conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin in murine primary hepatocytes and in\\xa0vivo in mice.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35251767'}, {'offsetInBeginSection': 259, 'offsetInEndSection': 457, 'text': 'One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31303442'}, {'offsetInBeginSection': 528, 'offsetInEndSection': 1289, 'text': 'ng and NAFLD/NASH. Here, we studied the metabolic benefit of liver-specific STK25 inhibitors on NAFLD development and progression in a mouse model of diet-induced obesity.METHODS: We developed a hepatocyte-specific triantennary N-acetylgalactosamine (GalNAc)-conjugated antisense oligonucleotide (ASO) targeting Stk25 and evaluated its effect on NAFLD features in mice after chronic exposure to dietary lipids.RESULTS: We found that systemic administration of hepatocyte-targeting GalNAc-Stk25 ASO in obese mice effectively ameliorated steatosis, inflammatory infiltration, hepatic stellate cell activation, nutritional fibrosis, and hepatocellular damage in the liver compared with mice treated with GalNAc-conjugated nontargeting ASO, without any systemic tox', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30576769'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': 'Triantennary N-acetyl galactosamine (GalNAc, GN3: ), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6-10-fold in mouse liver.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24992960'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 246, 'text': 'TriantennaryN-acetyl galactosamine (GalNAc, GN3) and lipophilic ligands such as cholesterol and\u03b1-tocopherol conjugations dramatically improve the distribution and efficacy of second-generation antisense oligonucleotides (ASOs) in the whole liver.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26907624'}]\n\n\n                 'What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"hepatocytes\", \"liver cells\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 160, 'offsetInEndSection': 347, 'text': 'Xist encodes a long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of Xist RNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29237010'}, {'offsetInBeginSection': 446, 'offsetInEndSection': 628, 'text': 'XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X chromosome and is involved in the X-inactivation process.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12492109'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 375, 'text': 'XIST encodes a functional RNA that is expressed exclusively from the inactive X in female mammals and is required for the silencing of most of the genes on the chromosome. XIST transcripts remain in the nucleus, and their specific localization to the inactive X is important for silencing; however, it is not known how these transcripts localize to the inactive X chromosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12900550'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 115, 'text': 'Dosage compensation in mammals is achieved by the transcriptional inactivation of one X chromosome in female cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12429693'}, {'offsetInBeginSection': 516, 'offsetInEndSection': 1143, 'text': 'Silencing on the inactive X chromosome coincides with the acquisition of a multitude of chromatin modifications, resulting in the formation of extraordinarily stable facultative heterochromatin that is faithfully propagated through subsequent cell divisions. The integration of all these processes requires a region of the X chromosome known as the X-inactivation center, which contains the Xist gene and its cis-regulatory elements. Xist encodes an RNA molecule that plays critical roles in the choice of which X chromosome remains active, and in the initial spread and establishment of silencing on the inactive X chromosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12429693'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'X-inactive-specific transcript (Xist) is a long noncoding RNA (lncRNA) essential for inactivating one of the two X chromosomes in mammalian females.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30496473'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 227, 'text': 'X-inactive specific transcript (Xist) long noncoding RNA (lncRNA) is thought to catalyze silencing of X-linked genes in cis during X-chromosome inactivation, which equalizes X-linked gene dosage between male and female mammals.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26739568'}, {'offsetInBeginSection': 166, 'offsetInEndSection': 360, 'text': 'In eutherian mammals X inactivation is regulated by the X-inactive specific transcript (Xist), a cis-acting non-coding RNA that triggers silencing of the chromosome from which it is transcribed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17333537'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 451, 'text': ' The X-linked Xist long non-coding RNA functions as an X inactivation master regulator; Xist is selectively upregulated from the prospective inactive X chromosome and is required in cis for X inactivation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26477563'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 231, 'text': 'The long noncoding X-inactivation-specific transcript (Xist gene) is responsible for mammalian X-chromosome dosage compensation between the sexes, the process by which one of the two X chromosomes is inactivated in the female soma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26489649'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 223, 'text': 'X chromosome inactivation (X-inactivation) is triggered by X-linked noncoding Xist RNA, which is expressed asymmetrically from one of the two X chromosomes in females and coats it in cis to induce chromosome-wide silencing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25747039'}, {'offsetInBeginSection': 459, 'offsetInEndSection': 651, 'text': ' X-inactive specific transcript (Xist) lncRNA accumulation (called an Xist cloud) on one of the two X-chromosomes in mammalian females is a critical step to initiate X-chromosome inactivation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25489864'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'X-inactive specific transcript (Xist) is a long noncoding RNA that is essential for initiating and maintaining epigenetic silencing of one copy of the X chromosome in mammalian females.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30539545'}, {'offsetInBeginSection': 81, 'offsetInEndSection': 192, 'text': 'Xist encodes a noncoding RNA that influences the probability that the cis-linked X chromosome will be silenced.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20657585'}, {'offsetInBeginSection': 187, 'offsetInEndSection': 309, 'text': 'Central to XCI is the long non-coding RNA Xist, which is highly and specifically expressed from the inactive X chromosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21626138'}, {'offsetInBeginSection': 145, 'offsetInEndSection': 406, 'text': 'While most genes are silenced on the inactive X chromosome, the gene for the long non-coding RNA XIST is silenced on the active X chromosome and expressed from the inactive X chromosome with which the XIST RNA associates, triggering silencing of the chromosome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25200388'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 330, 'text': 'In mammals, the process of X-chromosome inactivation ensures equivalent levels of X-linked gene expression between males and females through the silencing of one of the two X chromosomes in female cells. The process is established early in development and is initiated by a unique locus, which produces a long noncoding RNA, Xist.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25000994'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 323, 'text': 'The X inactive-specific transcript (Xist) gene is the master regulator of X chromosome inactivation in mammals. Xist produces a long noncoding (lnc)RNA that accumulates over the entire length of the chromosome from which it is transcribed, recruiting factors to modify underlying chromatin and silence X-linked genes in cis', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32482714'}, {'offsetInBeginSection': 118, 'offsetInEndSection': 341, 'text': 'This process, known as X-chromosome inactivation, relies on monoallelic activation of the Xist gene. Xist produces a non-coding RNA that can coat the chromosome from which it is transcribed in cis and trigger its silencing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20950563'}, {'offsetInBeginSection': 384, 'offsetInEndSection': 568, 'text': 'The process of inactivation is initiated by the long non-coding RNA X-inactive specific transcript (XIST) and achieved through interaction with multiple synergistic silencing pathways.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29701779'}, {'offsetInBeginSection': 470, 'offsetInEndSection': 628, 'text': 'The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X chromosome from which it is transcribed in cis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23166390'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'Xist (X-inactive specific transcript) plays a crucial role in X-inactivation. This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon differentiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14973270'}]\n\n\n                 'The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?'. \n                 Answer this question by returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question, \n                 ordered by decreasing confidence. The array should contain at max 5 elements but can contain less. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Long non-coding RNA\", \"lncRNA\", \"long non-coding (lnc) RNA\", \"long noncoding RNA\"]}"}]}
